ES2538335T3 - Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes - Google Patents
Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes Download PDFInfo
- Publication number
- ES2538335T3 ES2538335T3 ES13167597.7T ES13167597T ES2538335T3 ES 2538335 T3 ES2538335 T3 ES 2538335T3 ES 13167597 T ES13167597 T ES 13167597T ES 2538335 T3 ES2538335 T3 ES 2538335T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- composition
- use according
- amino
- methylpropanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002125 Sokalan® Polymers 0.000 title claims abstract description 35
- 239000004584 polyacrylic acid Substances 0.000 title claims abstract description 27
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims description 18
- 206010019973 Herpes virus infection Diseases 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 206010067152 Oral herpes Diseases 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 208000004898 Herpes Labialis Diseases 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 201000004946 genital herpes Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000000440 Herpetic Stomatitis Diseases 0.000 claims description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001610 denatonium benzoate Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 19
- 208000003251 Pruritus Diseases 0.000 description 12
- 206010065390 Inflammatory pain Diseases 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010033733 Papule Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000007391 self-medication Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010057372 Paraesthesia oral Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940075510 carbopol 981 Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002544 virustatic Substances 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13167597.7A EP2803354B1 (de) | 2013-05-14 | 2013-05-14 | Kombination aus Polyacrylsäure und 2-Amino-2-methylpropanol zur Verwendung in der Behandlung von Herpesinfektionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2538335T3 true ES2538335T3 (es) | 2015-06-19 |
Family
ID=48366229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13167597.7T Active ES2538335T3 (es) | 2013-05-14 | 2013-05-14 | Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160166603A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2803354B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016518424A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014267349A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112015028334A2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2538335T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014184223A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017212422A1 (en) * | 2016-06-08 | 2017-12-14 | Novartis Consumer Health Sa | Topical compositions comprising carbomer for the treatment and prevention of viral infections and allergic conditions |
| US20210330700A1 (en) * | 2020-04-23 | 2021-10-28 | Johnson & Johnson Consumer Inc. | Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols |
| DE102025101480A1 (de) | 2025-01-16 | 2026-07-16 | Pigmentsolution GmbH | Konservierungszusammensetzung |
| DE202026100173U1 (de) | 2025-01-16 | 2026-05-28 | Pigmentsolution GmbH | Rohr-im-Rohr-Homogenisierer |
| EP4778390A3 (de) | 2025-01-16 | 2026-08-12 | Pigmentsolution GmbH | Konservierungszusammensetzung |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2174242A (en) | 1937-08-13 | 1939-09-26 | Purdue Research Foundation | Aminoglycols |
| JPS6251617A (ja) * | 1985-08-30 | 1987-03-06 | Wako Pure Chem Ind Ltd | ビダラビンゲル軟膏 |
| JPS62263111A (ja) * | 1986-05-09 | 1987-11-16 | Shiseido Co Ltd | 粘性組成物 |
| US5075104A (en) * | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| US5622690A (en) * | 1990-04-05 | 1997-04-22 | Nurture, Inc. | Seed-derived proteinaceous compositions for reduction of sunburn cell formation |
| JPH08143460A (ja) * | 1994-11-17 | 1996-06-04 | Haruhito Miyata | 水虫類の治療方法及び用材 |
| JPH11511180A (ja) * | 1996-06-12 | 1999-09-28 | ストア ソシエテ アノニマ | 化粧品のための物理的殺菌用ゲル |
| US7442369B1 (en) * | 2000-08-09 | 2008-10-28 | Mcneil Ab | Compositions of minoxidil |
| JPWO2004069261A1 (ja) * | 2003-02-03 | 2006-05-25 | アリジェン株式会社 | 抗ヘルペスウイルス外用製剤の製造方法 |
| JP2005263695A (ja) * | 2004-03-18 | 2005-09-29 | Suiko Giken Kk | 水虫治療薬 |
| US20060229364A1 (en) * | 2005-03-10 | 2006-10-12 | 3M Innovative Properties Company | Antiviral compositions and methods of use |
| US8267927B2 (en) * | 2007-01-24 | 2012-09-18 | Koninklijke Philips Electronics N.V. | Advanced ablation planning |
| WO2010127033A1 (en) * | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| IT1395137B1 (it) * | 2009-08-05 | 2012-09-05 | Spider Biotech S R L | Nuovi peptidi antipatogeni |
| JP2011030981A (ja) * | 2009-08-06 | 2011-02-17 | Dainippon Printing Co Ltd | 皮膚貼付用組成物および皮膚貼付用材 |
| WO2012004669A1 (en) * | 2010-07-08 | 2012-01-12 | Devirex Ag | Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster |
| US20130072575A1 (en) * | 2011-09-19 | 2013-03-21 | Johnson & Johnson Consumer Companies, Inc. | Method and Composition for Treating Pain |
-
2013
- 2013-05-14 ES ES13167597.7T patent/ES2538335T3/es active Active
- 2013-05-14 EP EP13167597.7A patent/EP2803354B1/de not_active Not-in-force
-
2014
- 2014-05-14 AU AU2014267349A patent/AU2014267349A1/en not_active Abandoned
- 2014-05-14 US US14/891,102 patent/US20160166603A1/en not_active Abandoned
- 2014-05-14 BR BR112015028334A patent/BR112015028334A2/pt not_active Application Discontinuation
- 2014-05-14 WO PCT/EP2014/059813 patent/WO2014184223A1/de not_active Ceased
- 2014-05-14 JP JP2016513342A patent/JP2016518424A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015028334A2 (pt) | 2017-07-25 |
| EP2803354A1 (de) | 2014-11-19 |
| JP2016518424A (ja) | 2016-06-23 |
| WO2014184223A1 (de) | 2014-11-20 |
| EP2803354B1 (de) | 2015-03-04 |
| US20160166603A1 (en) | 2016-06-16 |
| AU2014267349A1 (en) | 2015-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2949139T3 (es) | Composición que elimina la congestión nasal y que tiene actividad antivírica | |
| US20090220440A1 (en) | Spray Composition for Topical Use for Treating and/or Preventing Herpes Simplex Labial Infections | |
| JP2016518424A (ja) | ヘルペス処置のための薬剤と方法 | |
| WO2011069184A1 (en) | Composition for treating skin lesions | |
| CN104337916A (zh) | 一种手脚冰凉及脚气的中药药剂 | |
| US9144612B2 (en) | Dermatological compositions containing an association of peroxide lipids and zinc, and uses thereof in particular in the treatment of labial and/or genital herpes | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| WO2016181355A1 (en) | Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity | |
| JP2012193159A (ja) | 鼻用スプレー | |
| US9901555B2 (en) | Treatment of viral infections | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| CN103153312A (zh) | 用于预防性治疗和治疗性治疗疱疹感染的吡罗昔康 | |
| KR20080053319A (ko) | 브리부딘을 함유하는 헤르페스 각막염 치료용 광안정 약학조성물 | |
| WO2011057363A1 (en) | Disposable device and uses thereof for skin and mucosal applications | |
| US20110070321A1 (en) | Method and Composition for Cutaneous Treatment of Herpes Simplex Infections | |
| US11951082B2 (en) | Composition of chlorhexidine | |
| WO2024261713A1 (en) | Topical regimen for treating cold sores | |
| ES2808864T3 (es) | Método para tratar enfermedades recurrentes de la piel y la membrana mucosa provocadas por HSV-1 y HSV-2 | |
| KR20180030482A (ko) | 점막 병변 치료를 위한 제형 | |
| EP3169324B1 (en) | Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof | |
| NZ614958B2 (en) | The treatment of viral infections |